These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32999024)

  • 121. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates.
    He W; Ou T; Skamangas N; Bailey CC; Bronkema N; Guo Y; Yin Y; Kobzarenko V; Zhang X; Pan A; Liu X; Xu J; Zhang L; Allwardt AE; Mitra D; Quinlan B; Sanders RW; Choe H; Farzan M
    Immunity; 2023 Oct; 56(10):2408-2424.e6. PubMed ID: 37531955
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
    Williams WB; Alam SM; Ofek G; Erdmann N; Montefiori DC; Seaman MS; Wagh K; Korber B; Edwards RJ; Mansouri K; Eaton A; Cain DW; Martin M; Hwang J; Arus-Altuz A; Lu X; Cai F; Jamieson N; Parks R; Barr M; Foulger A; Anasti K; Patel P; Sammour S; Parsons RJ; Huang X; Lindenberger J; Fetics S; Janowska K; Niyongabo A; Janus BM; Astavans A; Fox CB; Mohanty I; Evangelous T; Chen Y; Berry M; Kirshner H; Van Itallie E; Saunders KO; Wiehe K; Cohen KW; McElrath MJ; Corey L; Acharya P; Walsh SR; Baden LR; Haynes BF
    Cell; 2024 Jun; 187(12):2919-2934.e20. PubMed ID: 38761800
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.
    MacLeod DT; Choi NM; Briney B; Garces F; Ver LS; Landais E; Murrell B; Wrin T; Kilembe W; Liang CH; Ramos A; Bian CB; Wickramasinghe L; Kong L; Eren K; Wu CY; Wong CH; ; Kosakovsky Pond SL; Wilson IA; Burton DR; Poignard P
    Immunity; 2016 May; 44(5):1215-26. PubMed ID: 27192579
    [TBL] [Abstract][Full Text] [Related]  

  • 124. HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.
    Wang S; Matassoli F; Zhang B; Liu T; Shen CH; Bylund T; Johnston T; Henry AR; Teng IT; Tripathi P; Becker JE; Changela A; Chaudhary R; Cheng C; Gaudinski M; Gorman J; Harris DR; Lee M; Morano NC; Novik L; O'Dell S; Olia AS; Parchment DK; Rawi R; Roberts-Torres J; Stephens T; Tsybovsky Y; Wang D; Van Wazer DJ; Zhou T; Doria-Rose NA; Koup RA; Shapiro L; Douek DC; McDermott AB; Kwong PD
    Cell Rep; 2023 Jul; 42(7):112755. PubMed ID: 37436899
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.
    Cheng C; Duan H; Xu K; Chuang GY; Corrigan AR; Geng H; O'Dell S; Ou L; Chambers M; Changela A; Chen X; Foulds KE; Sarfo EK; Jafari AJ; Hill KR; Kong R; Liu K; Todd JP; Tsybovsky Y; Verardi R; Wang S; Wang Y; Wu W; Zhou T; ; Arnold FJ; Doria-Rose NA; Koup RA; McDermott AB; Scorpio DG; Worobey M; Shapiro L; Mascola JR; Kwong PD
    Cell Rep; 2020 Aug; 32(5):107981. PubMed ID: 32755575
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
    Xu K; Acharya P; Kong R; Cheng C; Chuang GY; Liu K; Louder MK; O'Dell S; Rawi R; Sastry M; Shen CH; Zhang B; Zhou T; Asokan M; Bailer RT; Chambers M; Chen X; Choi CW; Dandey VP; Doria-Rose NA; Druz A; Eng ET; Farney SK; Foulds KE; Geng H; Georgiev IS; Gorman J; Hill KR; Jafari AJ; Kwon YD; Lai YT; Lemmin T; McKee K; Ohr TY; Ou L; Peng D; Rowshan AP; Sheng Z; Todd JP; Tsybovsky Y; Viox EG; Wang Y; Wei H; Yang Y; Zhou AF; Chen R; Yang L; Scorpio DG; McDermott AB; Shapiro L; Carragher B; Potter CS; Mascola JR; Kwong PD
    Nat Med; 2018 Jun; 24(6):857-867. PubMed ID: 29867235
    [TBL] [Abstract][Full Text] [Related]  

  • 127. HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies.
    Sheward DJ; Hermanus T; Murrell B; Garrett N; Abdool Karim SS; Morris L; Moore PL; Williamson C
    J Virol; 2022 Jul; 96(14):e0032422. PubMed ID: 35758668
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.
    Yang Z; Li J; Liu Q; Yuan T; Zhang Y; Chen LQ; Lou Q; Sun Z; Ying H; Xu J; Dimitrov DS; Zhang MY
    PLoS One; 2015; 10(5):e0126428. PubMed ID: 26010511
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base.
    Corrigan AR; Duan H; Cheng C; Gonelli CA; Ou L; Xu K; DeMouth ME; Geng H; Narpala S; O'Connell S; Zhang B; Zhou T; Basappa M; Boyington JC; Chen SJ; O'Dell S; Pegu A; Stephens T; Tsybovsky Y; van Schooten J; Todd JP; Wang S; ; Doria-Rose NA; Foulds KE; Koup RA; McDermott AB; van Gils MJ; Kwong PD; Mascola JR
    Cell Rep; 2021 Apr; 35(1):108937. PubMed ID: 33826898
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
    Schiffner T; Phung I; Ray R; Irimia A; Tian M; Swanson O; Lee JH; Lee CD; Marina-Zárate E; Cho SY; Huang J; Ozorowski G; Skog PD; Serra AM; Rantalainen K; Allen JD; Baboo S; Rodriguez OL; Himansu S; Zhou J; Hurtado J; Flynn CT; McKenney K; Havenar-Daughton C; Saha S; Shields K; Schultze S; Smith ML; Liang CH; Toy L; Pecetta S; Lin YC; Willis JR; Sesterhenn F; Kulp DW; Hu X; Cottrell CA; Zhou X; Ruiz J; Wang X; Nair U; Kirsch KH; Cheng HL; Davis J; Kalyuzhniy O; Liguori A; Diedrich JK; Ngo JT; Lewis V; Phelps N; Tingle RD; Spencer S; Georgeson E; Adachi Y; Kubitz M; Eskandarzadeh S; Elsliger MA; Amara RR; Landais E; Briney B; Burton DR; Carnathan DG; Silvestri G; Watson CT; Yates JR; Paulson JC; Crispin M; Grigoryan G; Ward AB; Sok D; Alt FW; Wilson IA; Batista FD; Crotty S; Schief WR
    Nat Immunol; 2024 Jun; 25(6):1073-1082. PubMed ID: 38816615
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.
    Lyumkis D; Julien JP; de Val N; Cupo A; Potter CS; Klasse PJ; Burton DR; Sanders RW; Moore JP; Carragher B; Wilson IA; Ward AB
    Science; 2013 Dec; 342(6165):1484-90. PubMed ID: 24179160
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.
    Han Q; Jones JA; Nicely NI; Reed RK; Shen X; Mansouri K; Louder M; Trama AM; Alam SM; Edwards RJ; Bonsignori M; Tomaras GD; Korber B; Montefiori DC; Mascola JR; Seaman MS; Haynes BF; Saunders KO
    Nat Commun; 2019 Jul; 10(1):2898. PubMed ID: 31263112
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.
    Struwe WB; Chertova E; Allen JD; Seabright GE; Watanabe Y; Harvey DJ; Medina-Ramirez M; Roser JD; Smith R; Westcott D; Keele BF; Bess JW; Sanders RW; Lifson JD; Moore JP; Crispin M
    Cell Rep; 2018 Aug; 24(8):1958-1966.e5. PubMed ID: 30134158
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.
    Reiss EIMM; van Haaren MM; van Schooten J; Claireaux MAF; Maisonnasse P; Antanasijevic A; Allen JD; Bontjer I; Torres JL; Lee WH; Ozorowski G; Vázquez Bernat N; Kaduk M; Aldon Y; Burger JA; Chawla H; Aartse A; Tolazzi M; Gao H; Mundsperger P; Crispin M; Montefiori DC; Karlsson Hedestam GB; Scarlatti G; Ward AB; Le Grand R; Shattock R; Dereuddre-Bosquet N; Sanders RW; van Gils MJ
    NPJ Vaccines; 2022 Nov; 7(1):152. PubMed ID: 36433972
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.
    Madan B; Zhang B; Xu K; Chao CW; O'Dell S; Wolfe JR; Chuang GY; Fahad AS; Geng H; Kong R; Louder MK; Nguyen TD; Rawi R; Schön A; Sheng Z; Nimrania R; Wang Y; Zhou T; Lin BC; Doria-Rose NA; Shapiro L; Kwong PD; DeKosky BJ
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649208
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding.
    Bai H; Lewitus E; Li Y; Thomas PV; Zemil M; Merbah M; Peterson CE; Thuraisamy T; Rees PA; Hajduczki A; Dussupt V; Slike B; Mendez-Rivera L; Schmid A; Kavusak E; Rao M; Smith G; Frey J; Sims A; Wieczorek L; Polonis V; Krebs SJ; Ake JA; Vasan S; Bolton DL; Joyce MG; Townsley S; Rolland M
    Nat Commun; 2024 May; 15(1):3924. PubMed ID: 38724518
    [TBL] [Abstract][Full Text] [Related]  

  • 137. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
    Zhou T; Zheng A; Baxa U; Chuang GY; Georgiev IS; Kong R; O'Dell S; Shahzad-Ul-Hussan S; Shen CH; Tsybovsky Y; Bailer RT; Gift SK; Louder MK; McKee K; Rawi R; Stevenson CH; Stewart-Jones GBE; Taft JD; Waltari E; Yang Y; Zhang B; Shivatare SS; Shivatare VS; Lee CD; Wu CY; ; Mullikin JC; Bewley CA; Burton DR; Polonis VR; Shapiro L; Wong CH; Mascola JR; Kwong PD; Wu X
    Immunity; 2018 Mar; 48(3):500-513.e6. PubMed ID: 29548671
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.
    Crooks ET; Almanza F; D'Addabbo A; Duggan E; Zhang J; Wagh K; Mou H; Allen JD; Thomas A; Osawa K; Korber BT; Tsybovsky Y; Cale E; Nolan J; Crispin M; Verkoczy LK; Binley JM
    PLoS Pathog; 2021 Oct; 17(10):e1009807. PubMed ID: 34679128
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.
    Kwon YD; Pancera M; Acharya P; Georgiev IS; Crooks ET; Gorman J; Joyce MG; Guttman M; Ma X; Narpala S; Soto C; Terry DS; Yang Y; Zhou T; Ahlsen G; Bailer RT; Chambers M; Chuang GY; Doria-Rose NA; Druz A; Hallen MA; Harned A; Kirys T; Louder MK; O'Dell S; Ofek G; Osawa K; Prabhakaran M; Sastry M; Stewart-Jones GB; Stuckey J; Thomas PV; Tittley T; Williams C; Zhang B; Zhao H; Zhou Z; Donald BR; Lee LK; Zolla-Pazner S; Baxa U; Schön A; Freire E; Shapiro L; Lee KK; Arthos J; Munro JB; Blanchard SC; Mothes W; Binley JM; McDermott AB; Mascola JR; Kwong PD
    Nat Struct Mol Biol; 2015 Jul; 22(7):522-31. PubMed ID: 26098315
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
    Wang Q; Zhang S; Nguyen HT; Sodroski J
    J Virol; 2024 Feb; 98(2):e0159423. PubMed ID: 38289101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.